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ABSTRACT 23 
 24 
Annexins belong to an evolutionarily conserved multigene family of proteins expressed 25 
throughout the animal and plant kingdoms. Although they are soluble cytosolic proteins 26 
that lack signal sequences, they have also been detected in extracellular fluids and have 27 
been associated with cell surface membranes, where they could be involved in anti-28 
haemostatic and anti-inflammatory functions. Schistosome annexins have been 29 
identified on the parasite’s tegument surface and excretory/secretory products, but their 30 
functions are still unknown. Here we report the cloning, sequencing, in silico analysis, 31 
and functional characterization of a Schistosoma bovis annexin. The predicted protein 32 
has typical annexin secondary and tertiary structures. Bioassays with the recombinant 33 
protein revealed that the protein is biologically active in vitro, showing fibrinolytic and 34 
anticoagulant properties. Finally, the expression of the native protein on the tegument 35 
surface of S. bovis schistosomula and adult worms is demonstrated, revealing the 36 
possibility of exposure to the host’s immune system and thus offering a potential 37 
vaccine target for the control of schistosomiasis in ruminants. 38 
 39 
Keywords: Annexin; Schistosoma bovis; Plasminogen; Anticoagulant activity; 40 
Tegument. 41 
 42 
 43 
44 
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1. Introduction 45 
 46 
Schistosomiasis is a parasitic disease affecting man and domestic and wild animals 47 
that represents an important health and veterinary problem in many tropical and 48 
subtropical areas of the world. Schistosoma bovis is a cosmopolitan trematode of 49 
ruminants that can produce significant economic losses in endemic areas (Vercruysse 50 
and Gabriel, 2005). In addition, studies on S. bovis are interesting from the perspectives 51 
of both veterinary and human medicine because this species represents the genetic and 52 
immunological analogue of the important human pathogen S. haematobium (Agnew et 53 
al., 1989). 54 
Like all schistosome species, S. bovis adult worms can survive in host blood vessels 55 
for many years. In order to achieve such long survival times, parasites have molecules 56 
that allow them to modulate immune and haemostatic host responses to their own 57 
benefit (Pearce and MacDonald, 2002; Mountford, 2005; Secor, 2005; Ramajo-58 
Hernández et al., 2007; De la Torre et al., 2010). It is well known that a significant part 59 
of schistosome evasion mechanisms are achieved by the parasite’s inner and outer 60 
tegument surface (Abath and Werkhauser, 1997). The tegument, besides the gut, 61 
constitutes one of the most important host-parasite interchange surface, playing a role in 62 
the parasite’s nutrient uptake, excretion, osmoregulation, sensory reception, signal 63 
transduction, and interaction with the host’s immune and haemostatic systems (Jones  et 64 
al., 2004; van Hellemond et al., 2006; Ramajo-Hernández et al., 2007; De la Torre et al., 65 
2010). Thus, the tegument is a key parasite compartment to be mined for target 66 
molecules in the development of new anti-schistosome vaccines and drugs. With this 67 
aim, in the last years numerous investigations have focused on the identification and 68 
characterization of molecules expressed by schistosomes in their tegument and surface 69 
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membranes (van Balkom et al., 2005; Braschi et al., 2006; Braschi and Wilson, 2006; 70 
Pérez-Sánchez et al 2006, 2009; Skelly and Wilson, 2006; Mulvenna et al., 2010a; 71 
Castro-Borges et al., 2011). As a result, annexins have been one of the molecules 72 
frequently identified in the tegument of schistosomes.  73 
Annexins are Ca
2+
- and phospholipid-binding proteins that form an evolutionarily 74 
conserved multigene family, its members being expressed throughout the animal and 75 
plant kingdoms. Structurally, annexins are characterized by a highly α-helical and 76 
tightly packed protein core domain, considered to represent a Ca
2+
-regulated membrane-77 
binding module. Human annexins, designated A1 to A13 (except annexin A12, which  78 
is unassigned), have been implicated in a broad range of biological processes such as 79 
membrane trafficking and fusion, plasma membrane repair, anticoagulation, interaction 80 
with cytoskeletal proteins and signal transduction (Gerke and Moss, 2002; Moss and 81 
Morgan, 2004; Draeger et al., 2011). These soluble cytosolic proteins lack signal 82 
sequences that direct them to the classical secretory pathway. Nevertheless, some 83 
members of the family have consistently been identified in extracellular fluids. Binding 84 
sites for extracellular annexins exist on the cell surface and several possible functions 85 
for these proteins have been proposed. They include a role of annexin A5 as an 86 
anticoagulant protein, a function of annexin A2 as an endothelial cell-surface receptor 87 
for plasminogen and tissue-type plasminogen activator (t-PA), and the anti-88 
inflammatory activities of annexin A1 (Hajjar and Krishnan, 1999; Gerke and Moss, 89 
2002; Cederholm et al., 2007). 90 
Regarding schistosome annexins, several proteomic studies have identified them on 91 
the tegument surface of S. mansoni (Braschi and Wilson, 2006; Castro-Borges et al., 92 
2011) and S. japonicum (Mulvenna et al., 2010a), as well as in the excretion-secretion 93 
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products of S. bovis (Pérez.Sánchez et al., 2006). Moreover, in a recent survey of draft 94 
genomes for S. mansoni and S. japonicum (http://www.schistodb.org), Hoffmann et al. 95 
(2010) identified 14 annexins from S. mansoni, 6 from S. japonicum and 1 from S. 96 
haematobium. Of these, it is known that schistosome annexins 1, 3 and 5 are expressed 97 
on the tegument of the adult parasite (Braschi and Wilson, 2006; Mulvenna et al., 98 
2010a; Catro-Borges et al., 2011). Hofmann et al. (2010) reported that annexins are 99 
particularly noteworthy as surface-associated molecules of adult schistosomes and are 100 
likely to be an abundant surface-related molecule of digeneans such as the human liver 101 
fluke, Opistorchis viverrini, which also expresses abundant surface annexins (Mulvenna 102 
et al., 2010b). The physiological roles of these schistosome annexins are still unknown 103 
although it has been speculated that they could play important roles in surface 104 
maintenance, such as by ensuring the integrity of the membrane-membranocalyx 105 
complex (Braschi and Wilson, 2006). 106 
Unveiling the functions of schistosome annexins, and particularly whether they 107 
exhibit extracellular activities such as those reported for the annexins of other organisms 108 
(i.e., anticoagulant and fibrinolytic activities), is important as these extracellular 109 
activities could be vital for schistosome development and survival. Accordingly, the 110 
aims of the present work were to determine the physiological role of the annexin of S. 111 
bovis adult worms regarding its potential fibrinolytic and anticoagulant activities and to 112 
demonstrate its expression on the parasite surface at the host-parasite interface.  113 
 114 
2. Material and methods 115 
 116 
2.1. Parasite material 117 
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The life cycle of S. bovis was maintained at the laboratory by routine passage 118 
through sheep, golden hamsters, and the intermediate snail host Planorbarius 119 
metidjensis. Adult worms and lung schistosomula were recovered, respectively, from 120 
infected sheep and hamsters as described in De la Torre-Escudero at al. (2010). Briefly, 121 
lambs were infected with 2,000 cercariae and 4 months later they were sedated with 10 122 
mg of ketamine per kg of live weight and sacrificed by bleeding through the jugular 123 
vein. 124 
Adult worms were recovered from mesenteric veins and washed in warm 125 
phosphate buffered saline (PBS) pH 7.2 at 37ºC. Worms were inspected 126 
microscopically to verify their integrity and vitality, and immediately processed for 127 
RNA extraction, the collection of a tegument extract (TG), and immunolocalization 128 
studies. The tegument extract was obtained as described by Ramajo-Hernández et al. 129 
(2007). 130 
Lung schistosomula were obtained from hamsters, following the method of Gui 131 
et al. (1995). The animals were infected through the skin with 1,000 cercariae by  132 
bathing them individually (in a solution containing the cercariae) for 1 h. Six days after 133 
infection, the hamsters were euthanatized and their lungs were removed, minced and 134 
incubated in RPMI medium at 37ºC for two hours on a rocker-shaker. The suspension 135 
was sieved and live, intact schistosomula were collected with a 20 μl pipette. After three 136 
washes in warm PBS, they were fixed in 4% formalin and stored at 4°C until use.  137 
Animal experimentation was done according to the rules from the ethical and 138 
animal welfare committee from the institution where the experiments were conducted 139 
(IRNASA, CSIC), following the corresponding EU rules and regulations. 140 
 141 
2.2. RNA isolation, RT-PCR and cloning 142 
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Total RNA from adult worms was isolated using the NucleoSpin RNA II kit 143 
(Macherey-Nagel), following the manufacturer’s instruction, and preserved at -80ºC. 144 
 Reverse transcription was performed from total RNA using the first Strand 145 
cDNA Synthesis kit (Roche). For PCR amplification of S. bovis annexin cDNA, primers 146 
were designed from the S. mansoni and S. japonicum annexin sequences (GenBank 147 
AF065599 and AY813612, respectively). The forward primer (ANXFw, 5’- 148 
ATGGCYAAWRTTTCTGRATTTGG) was designed from the S. mansoni and S. 149 
japonicum annexin consensus sequence. This primer was used in two amplifications 150 
with two different reverse primers designed, respectively, from the S. mansoni and S. 151 
japonicum annexin sequences (ANXRev1, 5’-TTATTGTTCTTCATTATATATTTC; 152 
ANXRev2, 5’- TTATTCACCTAGACCACATAATG). 153 
PCR amplifications were performed in 35 cycles of 94ºC for 40 s, 42ºC for 40 s, 154 
and 72ºC for 1 min 30 s for the 5 first cycles, and 94ºC for 40 s, 48ºC for 40 s, and 72ºC 155 
for 1 min 30 s for the remaining 30 cycles. PCR products were electrophoresed in 156 
agarose gel and the cDNA band corresponding to the ANXFw/ANXRev2 amplification 157 
was purified from the gel using the StrataPrep DNA Gel Extraction kit (Stratagene). 158 
This PCR product was cloned into the pSC-A vector using the StrataClone PCR 159 
Cloning kit (Stratagene), following the manufacturer’s instruction, and sequenced on 160 
both strands. At least three different clones of the insert were sequenced to check for 161 
errors caused by PCR amplification. 162 
 163 
2.3. Bioinformatic analysis  164 
The deduced amino-acid sequence of S. bovis annexin (SbANX) was analyzed 165 
as follows: BLAST searching of the most similar sequences were conducted in the 166 
Swissprot/Uniprot and SchistoDB databases (http://www.uniprot.org/ and   167 
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http://www.genedb.org/Homepage/Smansoni); analysis of conserved domains was 168 
performed using SMART at http://smart.embl-heidelberg.de; theoretical isoelectric 169 
point (pI) and molecular weight (MW) calculations at 170 
http://www.expasy.org/tools/pi_tool.html; prediction of transmembrane helices using 171 
the TMHMM Server v. 2.0 at http://www.cbs.dtu.dk/services/TMHMM-2.0;  prediction 172 
of signal peptides with SignalP 3.0  (Bendtsen et al., 2004) at  173 
http://www.cbs.dtu.dk/services/SignalP, and search for glycosyl-phosphatidyl anchors 174 
in the sequence with the big-PI Predictor (Eisenhaber et al., 2000) at 175 
http://mendel.imp.ac.at/sat/gpi/gpi_server.html. 176 
The amino acid sequence and secondary structure of the SbANX were compared 177 
to those of four parasite and human annexins known to possess fibrinolytic or 178 
anticoagulant activities, namely, the Taenia solium  B1 and B2 (ANX B1, ANX B2) and 179 
the human A2 and A5 (ANX A2, ANX A5). Multiple sequence alignment of all these 180 
five annexins was done with ClustalW 2.1 at 181 
http://www.ebi.ac.uk/Tools/msa/clustalw2/. For the prediction of the secondary 182 
structures and three-dimensional modelling, the amino acid sequences were submitted 183 
to the Swiss-Model server (Arnold et al., 2006) at http://swissmodel.expasy.org/. The 3-184 
D models were visualized using the Pymol package (DeLano, 2002). 185 
 186 
2.4. Expression and purification of recombinant annexin and polyclonal antibody 187 
production 188 
The full-length cDNA sequence of SbANX was subcloned into the expression 189 
vector pQE-30 (Qiagen) and expressed in Escherichia coli M15 cells (Qiagen). For this, 190 
two new primers were designed from the S. bovis complete annexin sequence that 191 
contained KpnI adapters to assist in the subclonning (sense primer; 5´- 192 
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GGGGTACCATGGCTAATGTTTCTGAATTTGG; antisense primer, 5´- 193 
GGGGTACCTTATTCACCAAGTAGAACAC) (underlined letters represent the 194 
restriction enzyme sites). The complete cDNA coding sequence of S. bovis annexin was 195 
amplified from the SbANX-pSC-A construction. PCR amplification was accomplished 196 
under the following conditions: 35 cycles of 94ºC for 15 s, 64ºC for 30 s and, 72ºC for 197 
40 s. The amplified product was purified using the DNA Gel extraction kit (Stratagene) 198 
and digested with KpnI restriction endonuclease (Roche). After digestion, the PCR 199 
product was purified again from agarose gel and ligated to the KpnI predigested pQE-30 200 
vector. This construct was used to transform E. coli M15 cells. Single recombinant 201 
clones were selected and plasmid DNA extracted and sequenced to confirm the presence 202 
and the correct orientation of the SbANX cDNA insert. 203 
Expression was then induced in correctly transformed E. coli M15 cells by 204 
adding isopropyl β-d-thiogalactopyranoside (IPTG) at a final concentration of 1 mM at 205 
37ºC for 3h. The induced cells were harvested and lysed by sonication in a lysis buffer 206 
containing 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.9. After a 15 min 207 
centrifugation step at 40,000g, the lysate pellet was solubilised in binding buffer 208 
containing 100 mM NaH2PO4, 10 mM Tris-Cl, and 8M urea, and re-centrifuged as 209 
above. The new supernatant was passed through His-Bind resin (Qiagen) according to 210 
the manufacturer’s instructions. Before elution of the recombinant, urea was eliminated 211 
by washing the column with wash buffer (100 mM NaH2PO4, 10 mM Tris-Cl, pH 6.3) 212 
containing decreasing concentrations of urea (6M, 4M, 2M). Then, the recombinant 213 
protein was eluted with elution buffer (250 mM imidazole, 0.5 M NaCl, 50 mM 214 
NaH2PO4, pH 7.9). The eluted rSbANX was dialysed against PBS for 24 h at 4ºC and 215 
stored at -80ºC until use. The concentration of the recombinant protein was measured 216 
using the DC Protein assay kit (Bio-Rad) and its purity was checked by SDS-PAGE. 217 
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Once the recombinant protein had been obtained, and in order to have a specific 218 
probe for immunofluorescence studies, a polyclonal rabbit serum against S. bovis 219 
annexin (rSbANX) was obtained. To accomplish this, two rabbits (New Zealand) were 220 
immunized subcutaneously with three doses of 100 g of rSbANX, together with 221 
Freund’s adjuvants. The first dose was administered with the complete adjuvant, the 222 
second one with incomplete adjuvant and the third one only in PBS. The rabbits were 223 
bled at 15 days after the third dose and the antibody titre was determined by ELISA, 224 
using a standard protocol (Oleaga-Pérez et al., 1994). 225 
The reactivity and specificity of the polyclonal serum was tested by Western 226 
blotting against rSbANX and a tegument extract (TG) from adult worms following the 227 
protocol described by De la Torre-Escudero et al (2010). In this case the anti-rSbANX 228 
rabbit serum was used at a dilution of 1/1,600 and the peroxidase-conjugated anti-rabbit 229 
antibody (Sigma) was diluted at 1/1,000. 230 
 231 
2.5. Bioassays with rSbANX 232 
 233 
2.5.1. Plasminogen binding assays.  234 
The binding of rSbANX to plasminogen was assessed by ELISA in a similar 235 
way to that described for the S. bovis enolase (De la Torre-Escudero et al., 2010). 236 
Briefly, plate wells were coated with 0.5 µg of rSbANX and non-specific binding sites 237 
were blocked with 1% BSA in PBS (PBS-BSA). After washing, the different wells were 238 
incubated with increasing amounts (from 0 to 3 µg) of human plasminogen (Acris 239 
Antibodies) diluted in PBS-BSA. After a new wash, the wells were incubated with 240 
peroxidase-conjugated goat anti-human plasminogen IgG (Cedarlane Laboratories) 241 
diluted 1/2,000 in PBS-BSA and finally ortho-phenylenediamine (OPD) was used as a 242 
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chromogenic substrate for peroxidase. The plate included negative control wells, coated 243 
only with BSA, and positive control wells, coated with 1 μg of TG extract. 244 
To assess whether plasminogen binding to rSbANX occurs through lysine 245 
residues, a similar assay was performed in which the plate wells were coated with 0.5 246 
µg of rSbANX and incubated with 0.5 µg of plasminogen and increasing concentrations 247 
(from 0 to 60 mM) of ε-aminocaproic acid (εACA, Sigma). εACA is a lysine analogue 248 
that competitively inhibits plasminogen from binding to its receptor. Then, bound 249 
plasminogen was developed by incubating with peroxidase-conjugated goat anti-human 250 
plasminogen IgG and OPD. Similarly, BSA-coated wells were used as negative 251 
controls. 252 
 253 
2.5.2. Plasminogen activation assays. 254 
The effect of rSbANX on plasminogen activation and plasmin generation was 255 
evaluated by measuring the amidolytic activity of newly generated plasmin on the 256 
chromogenic substrate D-Valyl-L-leucyl-L-lysine 4-nitroanilide dihydrochloride 257 
(Sigma). This assay was performed on ELISA plates according to the protocol described 258 
previously (Mundodi et al., 2008). 259 
In each plate well, 2 µg of plasminogen, 3 μg of chromogenic substrate, 1 g of 260 
rSbANX, and 15 ng of tissue-type plaminogen activator (t-PA) (Acris antibodies) were 261 
mixed in a total volume of 150 μl of PBS and incubated at room temperature. In a 262 
parallel assay, plasmin generation was measured in the absence of t-PA, in the absence 263 
of rSbANX, and substituting annexin by BSA or by the buffer in which the rSbANX 264 
had been dissolved. Plasmin generation was monitored by quantifying the hydrolysis of 265 
the substrate through absorbance measurements at 405 nm every 30 min over two hours 266 
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as from the time the reaction began. Each reaction was analysed in quadruplicate and 267 
the whole assay was repeated three times. 268 
 269 
2.5.3. Prothrombin time and activated partial thromboplastin time of rSbANX. 270 
The anticoagulant activity of rSbANX was analysed in two coagulation tests for 271 
general screening such as the prothrombin time (PT) and the activated partial 272 
thromboplastin time (aPTT) tests. The PT and aPTT tests respectively detect 273 
disturbances in the extrinsic and intrinsic coagulation pathways. These tests measure the 274 
time elapsed between the addition of the corresponding coagulation initiation reagent 275 
(STA neoplastin plus or STA aPTT; Roche Diagnostics) to the plasma sample and clot 276 
formation. The PT results can also be expressed as a percentage of the normal activity. 277 
To carry out these tests, plasma samples were obtained from lamb blood 278 
extracted in polypropylene tubes containing sodium citrate. The samples analysed 279 
consisted of 500 µl of plasma with increasing amounts of rSbANX (from 0 to 80 280 
µg/ml). Two series of control samples were included in the analysis: one series 281 
contained BSA instead of rSbANX, and the other one contained no protein but 282 
equivalent volumes of the buffer in which the rSbANX had been dissolved.  283 
Each sample was analysed in duplicate and the assays were repeated twice. 284 
Samples were analysed with the STA-R Evolution® analyser (Diagnóstica Stago, Inc.). 285 
 286 
2.6. Immunolocalization of annexin in adult worms and lung-stage schistosomula 287 
Tissue expression of annexin was determined in adult worms and schistosomula 288 
by indirect immunofluorescence and later analysis by confocal microscopy. The study 289 
was carried out on sections of adult worms, on whole adult worms, and on 6-day old 290 
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lung schistosomula. The worms were fixed in formaldehyde buffered at 4% for either 5 291 
h (schistosomula) or 24 h (adults). 292 
For assays on adult sections, the worms were dehydrated and embedded in 293 
paraffin following standard protocols. Microtome-cut 5-μm sections were placed on 294 
microscope slides, deparaffinised in xylene, and rehydrated. The sections were then 295 
blocked with 1% BSA in PBS containing 0.05% Tween 20 (PBST)  for 1 h at 37ºC, 296 
after which they were incubated with the anti-rSbANX rabbit serum diluted 1/50 in 297 
blocking buffer for 1 h at 37ºC. Samples were washed three times with PBST and 298 
incubated at 4ºC overnight with an anti-rabbit IgG antibody conjugated to Alexa Fluor 299 
594 (Invitrogen) diluted 1/400 in blocking buffer containing phalloidin-Alexa Fluor 488 300 
(Invitrogen) diluted 1/200, which binds to actin microfilaments. The samples were then 301 
washed four times and mounted in antifade reagent (Prolong Gold, Invitrogen). All 302 
incubations were performed in a humid chamber. 303 
A similar protocol was followed for whole-mount assays. The reactions were 304 
performed in 1.5-ml test tubes containing 100 schistosomula or 5 adult pairs each. Fixed 305 
parasites were blocked for 2 h at room temperature, incubated with the anti- rSbANX 306 
serum overnight at 4ºC, and then with the above-mentioned Alexa Fluor reagents, both 307 
at a 1/300 dilution, for 4 h at room temperature. Whole parasites were washed five times 308 
and then mounted in antifade reagent (schistosomula) or in PBS (adult worms). In each 309 
assay, serum from a non-immunized rabbit was used as a negative control. Samples 310 
were analysed with a Leica TCS-NT confocal microscope. 311 
 312 
2.7. Statistics 313 
The results of the PT and aPTT coagulation tests were first analysed with the 314 
one-way ANOVA test, and when significant differences were found a post hoc analysis 315 
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with the HDS Turkey test was conducted to determine the causes of the significance. A 316 
similar procedure was applied to check whether there were any significant differences 317 
as a function of the amount of rSbANX added to the plasma samples and, if so, to 318 
establish which rSbANX concentration provided significantly different results. 319 
 320 
3. Results 321 
 322 
3.1. Cloning and in silico characterization 323 
 The ANXFw/ANXRev2 primer pair amplified a 1080 bp cDNA fragment 324 
compatible with the expected size for a schistosome annexin and an open reading frame 325 
coding for a protein of 359 amino acids, with a predicted MW and pI of 40,663 Da and 326 
5.85, respectively (GenBank accession number EU595758).  327 
 BLAST searching of the SWISS-Prot database with the deduced amino acid 328 
sequence of SbANX retrieved numerous annexins from different species. S. bovis 329 
annexin showed the highest identity percentages with the S. mansoni (Q9XY89) and S. 330 
japonicum (AAW25344) annexins (91% and 86%, respectively). Similarly, BLAST 331 
searching of the SchistoDB database retrieved several annexin sequences including the 332 
14 annexins sequences of S. mansoni reported by Hofmann et al.  (2010). Among them, 333 
the sequence showing the highest identity (91%) was Sm_074150, which corresponds to 334 
sequence Q9XY89 from the SWISS-Prot database; the remaining 13 sequences 335 
retrieved showed lower identities (from 37% to 23%). 336 
 Regarding non-schistosome helminths, SbANX showed the greatest identity to 337 
Taenia solium ANX B1 and B2 (42% and 36%, respectively). Finally, SbANX showed 338 
between 37% and 23% sequence identity to human annexins A1-A13, in particular 37% 339 
to ANX A5 and 32% to ANX A2. 340 
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Fig. 1A shows the alignment of SbANX with T. solium B1 and B2 and human 341 
A2 y A5 annexins. The SbANX contained a 309-amino acid core domain and a 50-342 
amino acid tail at its N-terminus. The core domain contained the four typical annexin 343 
repeats and each repeat harboured type II and III Ca
2+
-binding sites (Fig. 1A, yellow-344 
shaded and underlined residues, respectively). Type II calcium-binding sites were 345 
characterized by the M-K/R-G/R-X-G-T-(38 residues)-D/E sequence motif, and type III 346 
sites by the G-X-G-T-D/E sequence motif. In SbANX, each annexin repeat contained 347 
between 52 and 60 amino acid residues, mapping in the following sequence segments: 348 
51-103, 123-183 229-281 and 304-356 amino acid. The E-values for the four annexin 349 
repeats ranged from 2.70e
-20
 to 113e
-04. 
(Fig. 1A). 350 
 The SbANX contains the KGLGT sequence motif within repeat II of the core 351 
domain as T. solium ANX B1 and human A2 annexins. In human A2 annexin, this motif 352 
and the aspartic acid located at position162 (D
162
) appear to be required for the 353 
interaction of annexin with cell surface phospholipids (Fig. 1A) (Hajjar and Krishnan, 354 
1999).  355 
 The SbANX also had the 
100
LCQL
103
/
114
SL
115 
sequence motif, which showed 356 
50% identity with the 
8
LCKLSL
13
 sequence motif of human ANX A2. This motif is 357 
responsible for the interaction between human ANX A2 and t-PA (Hajjar et al., 1998).  358 
A similar motif (
38
LCK
40
/
69
SL
70
) is also displayed by the T. solium
 
ANX B2. In Fig. 1B, 359 
the above-mentioned motif is highlighted only in the 3D model of SbANX, but not in 360 
that of ANX A2 because this molecule was modelled from the 32
st
 amino acid onwards 361 
not including the N-terminus fragment in with the motif is located. 362 
 SbANX and T. solium ANX B1 and B2 have an insert fragment in the linker 363 
region between repeats II and III, which is absent from human annexins (Figs. 1A and 364 
1B).  365 
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 In silico secondary structure prediction revealed that SbANX was mainly made 366 
up of α-helices although four beta sheets are also included. The model does not predict 367 
secretory signal, transmembrane helices or glycosyl-phosphatidyl inositol anchors. The 368 
secondary and tertiary structures of these annexins are highly conserved even though 369 
their amino acid sequence identity only ranges between 32% and 42% (Fig. 1). The 370 
alignment in Fig. 1A shows that the four typical annexin repeats and the predicted α-371 
helices match in the five sequences. In Fig. 1B it can be observed that the four repeats 372 
are packed in a structure that resembles a flattened disc, with a slightly convex surface 373 
on which the Ca
2+
-binding loops are located, together with a concave surface where the 374 
amino and carboxyl termini come into close opposition.  375 
 376 
3.2. Expression and purification of recombinant S. bovis annexin 377 
 The full length SbANX cDNA was sub-cloned into the expression vector pQE-378 
30 and transformed into M15 E. coli host cells. The his-tagged recombinant protein 379 
(rSbANX) was expressed abundantly, although it was 100% insoluble. After 380 
solubilisation and purification under denaturing conditions, 5.7 mg of protein per litre of 381 
cell culture was obtained. The purified rSbANX migrated as a single band of 39 kDa by 382 
SDS-PAGE. 383 
 384 
3.3. Plasminogen binding and activation assays 385 
The plasminogen-binding assays showed that plasminogen bound to rSbANX 386 
and that the amount of plasminogen bound increased with the rising amount of 387 
plasminogen added to the reaction medium. Likewise, in the plate wells in which 388 
tegument extract (TG) was included as a positive control in the assay the binding of the 389 
plasminogen to such proteins was observed. In the negative control wells, coated only 390 
17 
 
with BSA, unspecific binding of plasminogen did not occur (Fig. 2A). Competition 391 
experiments with εACA revealed that plasminogen binding occurred through lysine 392 
residues, and that 10 mM of ACA completely inhibited the binding of plasminogen to  393 
rSbANX (Fig. 2B). 394 
Fig. 3 shows the results of the assays on plasminogen activation, in which it may 395 
be seen that rSbANX enhanced plasminogen activation in the presence of t-PA. It can 396 
also be observed that rSbANX was unable to activate plasminogen and generate 397 
plasmin in the absence of t-PA. In the controls, in which rSbANX was replaced by BSA 398 
or by buffer, no reactivity was observed (not shown). 399 
 400 
3.4. Anticoagulant activity 401 
To investigate the anticoagulant effect of rSbANX, we evaluated the inhibition 402 
of blood clotting in PT and aPTT assays (Figs. 4A and 4B). 403 
Both assays revealed significant differences (p < 0.01) between the samples with 404 
rSbANX and the controls with BSA or buffer. Additionally, there were no significant 405 
differences between either type of control sample (those containing BSA or buffer). 406 
The coagulant activity in the PT assay was lower in the plasma samples with 407 
rSbANX than in the controls and clearly decreased as the concentration of annexin 408 
increased. This difference was statistically significant (p < 0.01) in the samples 409 
containing a concentration of 80 µg/ml of annexin with respect to the controls without 410 
it. Likewise, coagulation time increased in parallel with the concentration of rSbANX. 411 
This increase in coagulation time was significant at rSbANX concentrations equal to or 412 
higher than 60 µg/ml (Fig. 4A). 413 
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The anticoagulant effect of rSbANX was considerably stronger in the aPTT 414 
assay. In this assay, the coagulation time was significantly longer (p < 0.01) as from an 415 
rSbANX concentration of 10 µg/ml in plasma (Fig. 4B). 416 
 417 
3.5. Reactivity and specificity of the anti-rSbANX rabbit hyperimmune sera 418 
The reactivity of the anti-rSbANX hyperimmune serum was tested in ELISA 419 
against the recombinant protein prior to its use in the immunolocalization assays. The 420 
antibody titre was 1/1,600. The specificity of the serum was assessed by Western 421 
blotting against the rSbANX and the native TG extracts from S. bovis adult worms. As 422 
shown in Fig. 5, the anti-rSbANX serum reacted strongly with the recombinant protein 423 
and specifically recognized the native annexin in the TG extract. The negative serum 424 
showed no reactivity with any of the proteins tested. 425 
 426 
3.6. Immunolocalization of S. bovis annexin 427 
Annexin localization in the parasite was analyzed in paraffin sections from adult 428 
worms, as well as in intact adult worms and 6-day-old lung schistosomula. 429 
The schistosomula incubated with the negative rabbit serum plus phalloidin (an 430 
actin ligand) only resulted in green fluorescence, indicating a lack of non-specific 431 
reactivity. The schistosomula incubated with the specific anti-rSbANX serum plus 432 
phalloidin showed actin reactivity in green, as well as the specific annexin reactivity 433 
(red) distributed on the tegument surface (Fig. 6). This figure shows the images 434 
obtained at each of the laser wavelengths -594 (red) and 488 (green)- since the merged 435 
image was difficult to interpret due to the co-localization of the specific reaction and the 436 
actin fluorescence. 437 
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Paraffin-embedded sections from adult worms incubated with the negative 438 
serum plus phalloidin resulted in green fluorescence on the outermost part of the 439 
tegument. Sections of male and female worms incubated with the specific anti-rSbANX 440 
serum plus phalloidin showed besides the actin reactivity in green the specific annexin 441 
reactivity, in red, abundantly distributed in internal tissues and also in the tegument 442 
surface. In male tegument, the red signal appears as discontinuous patches (arrows) and 443 
in female tegument, apparently, as a more continuous signal (Fig. 7A). 444 
Whole adult worms incubated with negative serum only showed the green 445 
florescence from actin. By contrast, adult worms incubated with the anti-rSbANX 446 
serum showed a red fluorescence pattern on the outermost part of the tegument. In 447 
males this pattern consisted of low abundant scattered tiny patches, and in females these 448 
patches were similarly distributed but more abundant (Fig. 7B). 449 
 450 
4. Discussion  451 
 452 
It is well known that schistosomes have adapted to the intravascular habitat of 453 
their hosts by developing mechanisms to modulate the haemostatic response. However, 454 
despite the relevance of the molecules involved in the biology of the parasite and their 455 
potential interest as vaccine antigens, these haemostatic molecules have aroused little 456 
attention. 457 
This prompted us to undertake studies of the interaction of S. bovis with the 458 
host’s haemostatic system. In previous work, we observed that adult worms activate the 459 
fibrinolytic system, presumably as a strategy to prevent the formation of clots around 460 
them, and that they did this through protein receptors for plasminogen expressed on the 461 
surface of their tegument, one of which has been determined to be enolase (Ramajo-462 
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Hernandez et al., 2007; De la Torre-Escudero et al., 2010). Here we wished to 463 
determine whether the annexin of S. bovis possesses any anti-haemostatic activity. In 464 
this sense, for some time it has been known that other annexins, such as the human A2 465 
and A5 and the B1 and B2 annexins of T. solium show anticoagulant and fibrinolytic 466 
activities (Hajjar et al., 1999; Gerke and Moss, 2002; Wang et al., 2006; Winter et al., 467 
2006). So we cloned and sequenced the S. bovis annexin cDNA and obtained a peptide 468 
sequence of 359 amino acids that displayed structural characteristics typical of the 469 
annexin family. That is, a core domain containing four typical annexin repeats 470 
characterized by alpha-helices and a variable N-terminal region (Gerke and Moss, 471 
2002). In this way, we confirmed the fact, already observed in vertebrate annexins, that 472 
the secondary and tertiary structures of annexins are highly conserved despite not 473 
showing high amino acid sequence identity among themselves (Moss and Morgan, 474 
2004).  475 
One particularity of the SbANX sequence, that human annexins do not have, is 476 
the long linker region between repeats II and III.  This characteristic is also seen in other 477 
schistosome annexins and in those of T. solium (Wang et al., 2006; Hofmann et al., 478 
2010; Tararam et al., 2010). As reported by Hofmann et al. (2010), these unique 479 
structural features combined with the immunogenic properties of several parasite 480 
annexins and unique epitopes not present in mammalian annexins may provide an 481 
opportunity to pursue these antigens as vaccine targets while preventing cross-reactivity 482 
with host annexins.  483 
Sequence analysis also revealed that SbANX lacks motifs for its transport or 484 
expression on the cell surface (signal peptide, transmembrane motif or GPI anchors), 485 
even though it is present on the surface of schistosomula and adult worms. This is not 486 
an isolated phenomenon since the same occurs with other annexins, and in particular 487 
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with human A2 annexin, which is constitutively expressed on the endothelial cell 488 
surface and the mechanism of its export from the cell is unknown. It has been described 489 
that human annexin A2 interacts with cell surface phospholipids via a calcium-490 
dependent binding site that includes 
119
KGLGT
123
 residues and the coordinating D
162
 of 491 
core repeat 2 (Hajjar and Krishnan, 1999). In the S. bovis annexin we found the same 492 
motif in residues 120-124 (
120
KGLGT
124
) as well as a D
167
.  It is therefore possible that 493 
this motif could be responsible for the interaction between the S. bovis annexin and the 494 
phospholipids of the plasma membrane at the surface of the tegument of the worms, 495 
although confirmation of this point requires additional studies. 496 
The plasminogen binding and activating assays indicated that the S. bovis 497 
annexin, like the human A2 annexin (Hajjar et al., 1998), had fibrinolytic activity. It 498 
was observed that rSbANX binds plasminogen through lysine residues and that it 499 
enhanced t-PA mediated plasminogen activation. This is the first time that 500 
profibrinolytic activity has been demonstrated in an annexin of parasite origin, and 501 
particularly in a schistosome species. 502 
Human A2 annexin interacts with t-PA through the 
8
LCKLSL
13
 motif present at 503 
the N-terminal end (Hajjar et al., 1998). In the rSbANX sequence, a similar motif has 504 
been identified with an identity of 50% (
100
LCQL
103
/
114
SL
115
). However, despite this 505 
similarity it does not seem likely that this motif would be responsible for the interaction 506 
with t-PA since, as seen from the three-dimensional model of rSbANX, it is localized in 507 
a zone of the molecule that is not very accessible (Fig. 1B).     508 
The A5 extracellular annexin shows anticoagulant properties that depend on its 509 
Ca
2+
-regulated binding to anionic phospholipids; those exposed on the surface of 510 
activated platelets or endothelial cells. In the presence of Ca
2+
 annexin competitively 511 
binds to phospholipids with very high affinity and disturbs the form of some activated 512 
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coagulation complexes (Gerke and Moss, 2002). Regarding this type of activity, in 513 
known parasite annexins anticoagulant properties have only been demonstrated for the 514 
annexins B1 and B2 of T. solium (Wang et al., 2006). In S. bovis, the results of the PT 515 
and aPTT assays clearly demonstrate that rSbANX inhibits the extrinsic coagulation 516 
pathway and, more strongly, the intrinsic pathway. Inhibition of the extrinsic 517 
coagulation pathway was achieved with high concentrations of rSbANX (60-80 µg/ml), 518 
which were higher than those of T. solium annexin B2 producing the same effect (40 519 
µg/ml); by contrast, inhibition of the intrinsic pathway was achieved with quite lower 520 
rSbANX concentrations (10 µg/ml) as compared to T. solium annexin B1 (60 µg/ml) 521 
(Wang et al., 2006).    522 
Thus, this would be the first demonstration of anticoagulant activity by an 523 
annexin from a Schistosoma species. Additionally, bearing in mind the different 524 
functions of vertebrate annexins, it cannot be ruled out that S. bovis annexin could have 525 
additional activities, in particular some type of immunomodulatory activity, as has been 526 
demonstrated for the B1  T. solium annexin (Gao et al., 2007; Yan et al., 2008). 527 
It is evident that for these anticoagulant and fibrinolytic activities of SbANX to 528 
have relevant physiological roles, the SbANX should be exposed on the surface of the 529 
worm into contact with the host blood. As reported in different studies addressing the 530 
tegument of schistosomes, annexin has been identified on the tegument surface of adult 531 
worms and schistosomula of  S. mansoni and S. japonicum (Braschi and Wilson, 2006; 532 
Tararam et al., 2010; Castro-Borges et al., 2011). The SbANX immunolocalization 533 
studies performed in adults and schistosomula of S. bovis indicate that both 534 
developmental stages express this protein on the surface of their tegument. The 535 
schistosomula of S. bovis shows an annexin expression pattern similar to that of S. 536 
japonicum schistosomula, whereas on the surface of S. bovis adults the annexin is 537 
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expressed less abundantly than in S. japonicum adult worms (Tararam et al., 2010). 538 
Additionally, the SbANX described in this work is homologous to Smp_074150. This S. 539 
mansoni annexin was detected by mass spectrometry of material released by trypsin 540 
shaving of live S. mansoni (Castro-Borges et al., 2011), providing additional support to 541 
the notion that SbANX, as Smp_074150, might also be surface-located. 542 
Bearing in mind these results, it is somewhat surprising that annexin, despite 543 
being expressed on the surface of the tegument and also found in the secretion-excretion 544 
products, should not be immunogenic in natural infections by Schistosoma (Mutapi et 545 
al., 2005; Pérez-Sánchez et al., 2006). It would be interesting to test if vaccination with 546 
this protein will lead to its recognition by the host immune system allowing the 547 
evaluation of its protective potential against infections in ruminant schistosomiasis. 548 
In sum, here we have cloned, sequenced and characterized a S. bovis annexin. 549 
We show that, in vitro, the corresponding recombinant protein displays fibrinolytic and 550 
anticoagulant activities; that the native protein is expressed on the tegument surface of 551 
adult worms and schistosomula, and that it is therefore in direct contact with the host’s 552 
blood. All this suggests that this annexin could be used by S. bovis, together with other 553 
tegument proteins of proven fibrinolytic activity, such as enolase, to prevent thrombus 554 
formation and other haemostatic disturbances that could be lethal for the survival of the 555 
parasite in the bloodstream. The anti-haemostatic activities observed, and other potential 556 
immune modulatory functions make the S. bovis annexin and its homologues promising 557 
antigenic targets for development of new anti-schistosome vaccines. 558 
559 
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 677 
Figure legends. 678 
 679 
Figure 1. (A) Alignment of the SbANX (ACC78610) with annexins B1 (AAD34598) 680 
and B2 (AAY17503) from Taenia solium and human A2 (AAH09564) and A5 681 
(NP_001145). The conserved amino acids are labelled with asterisks; the conservative 682 
and semi-conservative substitutions are labelled with two and one points, respectively. 683 
Predicted α-helices are indicated in grey and -sheets in green. The four-repeat domains 684 
of the annexin sequence are indicated with a horizontal line over the conserved zone. 685 
The type II Ca
2+
- binding sites are shaded in yellow, and the type III Ca
2+
- binding sites 686 
are underlined. The t-PA-binding motif of human A2 annexin and other similar motifs 687 
identified in the SbANX  and in the T. solium B2 annexin are in red. The phospholipid-688 
binding motif of the cell surface identified in the human A2 annexin is boxed in. (B), 689 
Molecular modelling of S. bovis annexin and human A2 annexin.  The variable N-690 
terminal end is in black; and the annexin repeat domains I, II, III and IV  are in red, 691 
yellow, orange and blue respectively. The insert fragment in the linker region between 692 
repeats II and III is in green. 693 
 694 
Figure 2. (A) Plasminogen-binding assay to 0.5 g of rSbANX and incubation with 695 
increasing amounts of plasminogen, 0-3 g (). Positive control using 1 μg of tegument 696 
extract (TG) instead of rSbANX (X). Negative control coated with BSA (). (B) 697 
Competition assay. Wells coated with 0.5 g of rSbANX () or BSA ( ) were 698 
incubated with 0.5 g of plasminogen and increasing amounts of ACA. Each point is 699 
the mean of three replicates ± standard deviation.  700 
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 701 
Figure 3. Plasminogen activation assay with rSbANX or t-PA alone, rSbANX together 702 
with t-PA, and the negative control with the reaction substrate alone. Each point is the 703 
mean of four replicates ± standard deviation. The experiments were performed three 704 
times.  705 
Figure 4. Coagulation assays in plasma samples with increasing concentrations of 706 
rSbANX (0-80 µg/ml). (A) Prothrombin time assay (PT) expressed in time and 707 
percentage of activity. (B) Activated partial thromboplastin time (aPTT). () rSbANX, 708 
()BSA and (  ) buffer. Each point is the mean of two replicates ± standard deviation. 709 
The experiments were performed two times. * p < 0.001.  710 
 711 
Figure 5. Western blot for study of the specificity of an anti-rSbANX serum on the 712 
rSbANX and a tegument extract (TG) from S. bovis adult worms. 1, negative control 713 
sera; 2, anti-rSbANX rabbit serum at 1:1,600 dilution.  714 
 715 
Figure 6. Immunolocalization of S. bovis annexin in lung-schistosomula. Confocal 716 
microscope images of schistosomula after incubation with phalloidin-Alexa Fluor 488 717 
(green) plus the negative or the anti-rSbANX rabbit sera and an anti rabitt IgG-Alexa 718 
Fluor 594 (red). Magnification 600x.  719 
 720 
Figure 7. Immunolocalization of S. bovis annexin in adult worms. (A) Images of 721 
parasite sections, (B) magnification of the boxes highlighted in (A) showing the male 722 
and female tegument, and (C) images of whole parasites. Both, the sections and whole 723 
parasites were incubated with phalloidin-Alexa Fluor 488 (green) plus the negative or 724 
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the anti-rSbANX rabbit sera and an anti-rabbit IgG-Alexa Fluor 594 (red). The upper 725 
row of panels (A) and (C) shows the merged projected images derived from sections 726 
generated by the confocal microscope and the lower row shows the corresponding 727 
transmitted light images. Magnification 600x. 728 
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